New treatment before rectal surgery using radiation, chemo, and immunotherapy
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests giving radiation and chemotherapy plus an immunotherapy medicine called tislelizumab before surgery for locally advanced rectal cancer. It aims to shrink the tumor and increase the chance of fully removing it safely (R0 resection).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and can take and swallow study pills normally
- Your rectal cancer is confirmed as adenocarcinoma by tissue testing (biopsy/pathology)
- Your MRI shows the tumor is low in the rectum and you have higher-risk features (as defined by the study)
- You have not had any prior cancer treatment for rectal cancer (including surgery, radiation, chemo, targeted therapy, or immunotherapy)
- A doctor plans for you to have surgery after the pre-treatment is finished, with an expected complete removal (R0)
- You can do the study activities with good general health (ECOG performance status 0–1) and meet major safety checks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy, radiation, and an immunotherapy drug (tislelizumab) before surgery can improve outcomes for people with locally advanced rectal cancer that has specific protein/gene markers (pMMR or MSS). It’s designed for those who have not yet had any treatment for their cancer.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
This trial tests a combination of chemo, a medicine that blocks blood vessel growth, and an immune checkpoint drug given before rectal cancer surgery. It’s for people with locally advanced rectal cancer without distant spread, to try to shrink the tumor and improve surgical results.
This trial tests a combination of the immunotherapy drug tislelizumab with standard chemotherapy and radiation before surgery to see if it can help patients with low rectal cancer avoid surgery or keep their organs. It is for people whose tumors are close to the anus and have not spread.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.